Studies * START * Presentations

HIV Drug Therapy Glasgow 2016, 23-26 October 2016

Oral Presentation:
Initiation of ART early in HIV infection: START to Finish,
presented by Jens Lundgren on Monday 24 October 09.30-09:50

AIDS 2016, Durban, South Africa, July 2016

Oral Presentations:

Increased risk of suicidal behaviour with use of efavirenz: results from the START trial. Arenas-Pinto A et al. Presentation

Who benefited most from immediate treatment in START? A subgroup analysis. Molina J-M et al. Presentation

Poster Presentations:

The role of plasma HIV RNA and T cell subset counts/percent and ratio in explaining the benefit of immediate antiretroviral therapy (ART) initiation in HIV+ individuals with high CD4+ counts. Babiker A et al. Poster

Non-invasive serum markers suggest benefit for early ART initiation on liver fibrosis progression within the START study. Matthews G (Rockstroh J, presenting) et al. Poster

Deferred antiretroviral therapy is associated with lower estimated glomerular filtration rate in HIV-positive individuals with high CD4 counts. Mocroft A et al. Poster

Assessment of the impact of early ART on sexual behaviour in INSIGHT strategic timing of antiretroviral treatment (START) trial. Rodger A et al. Poster


Conference on Retroviruses and Opportunistic Infections (CROI) 2016, Boston, Massachusetts, February 2016

Oral Presentations:

Early antiretroviral therapy does not improve vascular function: a START substudy. Baker J et alPresentation

Immediate ART initiation reduces risk of infection-related cancer in HIV infection. Borges A et al. Presentation

Poster Presentations:

Changes in CVD risk factors with early and deferred ART in the START trial. Baker J et al. Poster

Increased quality of life with immediate ART initiation: results from the START trial. Lifson A et al. Post

Effect of immediate ART on risk of severe bacterial infections: the START trialO'Connor G et al, Poster


Baker J et al,